In contrast to ICI monotherapy, the dual blockade of PD-1/PD-L1 and CTLA-4 inhibitors operates at diverse stages of T cell activation and synergistically augments the immune response against cancer cells[137]. The gene discussed is CD274; the disease is cancer.